MYnd Analytics Inc (MYND) Director John Pappajohn Purchases 100,000 Shares

Share on StockTwits

MYnd Analytics Inc (NASDAQ:MYND) Director John Pappajohn purchased 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were acquired at an average cost of $1.68 per share, with a total value of $168,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ:MYND traded down $0.03 during trading hours on Friday, reaching $1.57. The stock had a trading volume of 74,645 shares, compared to its average volume of 260,189. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.13 and a quick ratio of 1.13. MYnd Analytics Inc has a 12-month low of $0.62 and a 12-month high of $4.08.

MYnd Analytics (NASDAQ:MYND) last released its earnings results on Tuesday, December 11th. The company reported ($0.20) earnings per share (EPS) for the quarter. MYnd Analytics had a negative return on equity of 430.80% and a negative net margin of 589.07%. The firm had revenue of $0.34 million during the quarter.

Separately, Maxim Group reissued a “buy” rating and issued a $5.00 target price on shares of MYnd Analytics in a research report on Thursday, December 13th.

ILLEGAL ACTIVITY WARNING: “MYnd Analytics Inc (MYND) Director John Pappajohn Purchases 100,000 Shares” was originally published by Zolmax and is the property of of Zolmax. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://zolmax.com/investing/mynd-analytics-inc-mynd-director-john-pappajohn-purchases-100000-shares/2966005.html.

About MYnd Analytics

MYnd Analytics, Inc operates as a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. It provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioural disorders, includes depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders.

Read More: No Load Funds

Receive News & Ratings for MYnd Analytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYnd Analytics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Amgen, Inc.  Shares Bought by Boenning & Scattergood Inc.
Amgen, Inc. Shares Bought by Boenning & Scattergood Inc.
Sandy Spring Bancorp Inc.  Stake Increased by BNP Paribas Arbitrage SA
Sandy Spring Bancorp Inc. Stake Increased by BNP Paribas Arbitrage SA
Netflix, Inc.  is Birinyi Associates Inc.’s 10th Largest Position
Netflix, Inc. is Birinyi Associates Inc.’s 10th Largest Position
Berman Capital Advisors LLC Raises Holdings in Nucor Co.
Berman Capital Advisors LLC Raises Holdings in Nucor Co.
BerganKDV Wealth Management LLC Increases Position in Cognizant Technology Solutions Corp
BerganKDV Wealth Management LLC Increases Position in Cognizant Technology Solutions Corp
Schwab Intermediate-Term U.S. Treasury ETF  Stake Increased by BerganKDV Wealth Management LLC
Schwab Intermediate-Term U.S. Treasury ETF Stake Increased by BerganKDV Wealth Management LLC


 
© 2006-2019 Zolmax.